Frontiers in pharmacology

Tirzepatide compared to other diabetes medicines for preventing foot problems in type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Up to 25% of patients with type 2 diabetes may experience diabetic foot complications.

  • Diabetic foot complications are a significant cause of health issues in patients with type 2 diabetes.
  • Tirzepatide has shown better blood sugar control compared to semaglutide.
  • The effects of tirzepatide on diabetic foot complications are not well understood.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Dec '24
Kidney health in type 2 diabetes with moderate heart risk using four common diabetes medicines
top 5% journal
cited by 5 papers
journal article
Aug '26
Comparing glucagon-like peptide-1 receptor drugs and other diabetes medicines in prostate cancer patients receiving hormone therapy
journal article
Sep '26
Tirzepatide and the risk of asthma attacks in people with type 2 diabetes
top 10% journal
journal article
Feb '26
Leg and foot problems in adults with type 2 diabetes using four common diabetes medicines: a trial-like comparison
top 20% journal
cited by 3 papers
journal article
Nov '25
Impact of Diabetes Medications on Leg Complications in Peripheral Artery Disease
top 10% journal
cited by 3 papers
journal article
May '24
How Different Diabetes Medicines Compare in Preventing Serious Vision Loss from Diabetic Eye Disease
top 5% journal
cited by 26 papers
multicenter study
Mar '24
Real-World Effects of Weekly GLP-1 Medicines Compared to DPP-4 Inhibitors on Blood Sugar and Weight in Type 2 Diabetes
top 30% journal
cited by 10 papers
observational study
Jun '25
SGLT2 Inhibitors, Increased Red Blood Cells, and Blood Clots in Adults with Type 2 Diabetes
top 2% journal
cited by 24 papers
journal article
Sep '26
Nerve problems in type 2 diabetes linked to GLP-1 receptor drugs compared to DPP-4 inhibitor drugs
top 10% journal
comparative study
May '25
Time until stronger treatment is needed with GLP-1 drugs versus other medicines in people with type 2 diabetes on metformin
top 20% journal
cited by 1 paper
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief